In Vivo Modulation of Intestinal CYP3A Metabolism by P-Glycoprotein: Studies Using the Rat Single-Pass Intestinal Perfusion Model
- 1 April 2003
- journal article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 305 (1) , 306-314
- https://doi.org/10.1124/jpet.102.044719
Abstract
P-Glycoprotein (P-gp) has been hypothesized to modulate intestinal drug metabolism by increasing the exposure of drug to intracellular CYP3A through repeated cycles of drug absorption and efflux. The rat single-pass intestinal perfusion model was used to study this interplay in vivo. N-Methyl piperazine-Phe-homoPhe-vinylsulfone phenyl (K77), a peptidomimetic cysteine protease inhibitor (CYP3A/P-gp substrate), and midazolam (CYP3A substrate) were each perfused through a segment of rat ileum alone and with the P-gp inhibitorN-{4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)-ethyl]-phenyl}-9,10-dihydro-5-methoxy-9-oxo-4-acridine carboxamine (GG918). Samples were obtained continuously from the outlet perfusate and the mesenteric vein at 5-min intervals for 40 to 60 min. The parent drug and two main metabolites of K77 (N-desmethyl and N-oxide) and midazolam (1-OH and 4-OH) were quantitated by liquid chromatography/mass spectrometry. K77 appearance in the mesenteric blood (Pblood = 5 ± 3 × 10−6 cm/s) was increased 3-fold with GG918, whereas midazolam permeability (Pblood = 1.1 ± 0.3 × 10−4 cm/s) was unchanged by GG918. K77 metabolites were preferentially excreted into the lumen, 4-OH midazolam was found equally in lumen and blood, and 1-OH was mainly excreted into blood. The extent of metabolism was estimated by calculating the fraction metabolized = 1 −Pblood/Plumen and the extraction ratio (ER) determined from the direct measurement of known metabolites as ER = sum metabolitesall/(sum metabolitesall + drug in blood). When P-gp was inhibited, the fraction metabolized for K77 was decreased (95 to 85%) and the ER tended toward a decrease, whereas no differences in either parameter were observed for midazolam (not a P-gp substrate). These data support a role for P-gp in modulating the extent of intestinal metabolism in vivo by controlling drug access to the enzyme.Keywords
This publication has 23 references indexed in Scilit:
- Intestinal Metabolism Promotes Regional Differences in Apical Uptake of Indinavir: Coupled Effect of P-Glycoprotein and Cytochrome P450 3A on Indinavir Membrane Permeability in RatThe Journal of Pharmacology and Experimental Therapeutics, 2002
- Unmasking the Dynamic Interplay between Intestinal P-Glycoprotein and CYP3A4The Journal of Pharmacology and Experimental Therapeutics, 2002
- The impact of P-glycoprotein efflux on enterocyte residence time and enterocyte-based metabolism of verapamilJournal of Pharmacy and Pharmacology, 2001
- Profound effect of plasma protein binding on the polarized transport of furosemide and verapamil in the Caco-2 model.Pharmaceutical Research, 2001
- BIOCHEMICAL, CELLULAR, AND PHARMACOLOGICAL ASPECTS OF THE MULTIDRUG TRANSPORTERAnnual Review of Pharmacology and Toxicology, 1999
- Interrelationship Between Substrates and Inhibitors of Human CYP3A and P-GlycoproteinPharmaceutical Research, 1999
- Intestinal drug metabolism and antitransport processes: A potential paradigm shift in oral drug deliveryJournal of Controlled Release, 1996
- Distribution and induction of CYP3A1 and CYP3A2 in rat liver and extrahepatic tissuesBiochemical Pharmacology, 1995
- CYP3A gene expression in human gut epitheliumPharmacogenetics, 1994
- Evaluation of the mass balance assumption with respect to the two‐resistance model of intestinal absorption by using in situ single‐pass intestinal perfusion of theophylline in ratsJournal of Pharmaceutical Sciences, 1992